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TOWARDS ITEM DEVELOPMENT FOR THE PSYCHOSOCIAL IMPACT OF ASSISTIVE 
DEVICES SCALE FOR CONTINENCE (C-PIADS) 
 
Hypothesis / aims of study 
Continence difficulties (CD) can have a negative impact on psychological and social functioning; they have been associated with 
elevated levels of stress, feelings of powerlessness, isolation and depression. Assistive devices (ATD) are extensively used in 
continence management, from implanted devices to absorbent pads. Unrestricted and facilitated participation in human life is 
essential in the technology user’s definition of quality of life outcomes (1), and it is therefore important to have valid, responsive 
and sensitive measures of psychosocial experiences associated with CD and its ATDs. Current outcome measures for continence 
ATDs do not adequately address psychosocial impact. Clinical assessment of treatment outcomes tend to focus on clinical issues 
and underestimate the degree of psychosocial impact perceived by patients (2) and although there are several validated 
instruments which are designed to assess the health-related quality of life, their validity for evaluating the effectiveness (especially 
the psychosocial impact) of assistive devices is unknown.  
The purpose of this study was to explore whether the Psychosocial Impact of Assistive Devices Scale (PIADS), which has been 
shown to reliably predict the adoption and use of ATDs (3), requires modification to address the particular needs of continence 
ATD users, and to inform any subsequent item development. The provision of such a tool will enable patient-centred evaluation 
of new and existing technologies and facilitate the establishment of a robust evidence base on which to base treatment decisions 
for individuals with CD.  
 
Study design, materials and methods 
The study was conducted in Ottawa, Canada and Bristol, UK. It employed interpretive methods in which qualitative information 
from semi-structured interviews (10 to 30 minutes) was combined with the findings from cognitive interviews for questionnaire 
pre-testing. A purposive sampling strategy was used to recruit individuals who could provide information rich interviews. The 
objective was to provide opportunities for interviewees to spontaneously (i.e. without reference to PIADS) identify important 
concerns and issues that should be considered for developing a version of the PIADS for continence technologies. Face-to-face 
interviews were audio taped with permission from participants and transcribed. Recordings of the interview sessions were 
subjected to qualitative content analysis. Common themes were identified.  
All participants at the Ottawa site and 20 of the 31 participants at the Bristol site were also asked to complete the PIADS while 
considering their currently used continence device by commenting on the suitability and appropriateness of PIADS for assessing 
quality of life outcomes resulting from their continence ATD and were encouraged to suggest supplemental items, (i.e. issues not 
represented in the PIADS).  
 
Results 
In Ottawa, 9 participants (M= 1; F= 8) were recruited with an average age of 80 years (63-86 years). In Bristol, 31 individuals, 
(M= 8; F= 23) were recruited with an average age of 56 years (17– 87 years). All interviewees self-reported CD and the use of 
ATDs to manage symptoms. All the participants at the Ottawa site used absorbent pads to manage their CD; at the Bristol site, 
24 participants used pads (2 were in addition to other continence devices), 6 used intermittent catheters, 2 used Foley catheters 
and 1 had an artificial sphincter. 
Semi-structured interviews: When prompted to describe their level of satisfaction with the technology, many participants indicated 
that they had no choice about their CD, and that the products were simply something that they “had to use”. Some expressed 
dissatisfaction with their products, e.g. pads were not comfortable in hot weather. In the UK, the cost of products was frequently 
mentioned, with participants indicating that they were not eligible to receive ‘free’ (i.e. NHS funded) products. Several participants 
were not aware of alternative ATDs or treatment and were told that “it's a natural part of aging”.  
Restrictions to social and recreational activities were frequently cited as the reason for seeking help from clinicians. Participants 
used words like "assurance", "freedom" and "empowerment" in describing what they would like their ATDs to give them and do 
for them, and the need to strategize arose from an ever-present concern that one might have an accident and be embarrassed in 
public. Participants described how anxieties about others finding out about their CD, due to leakage, odour or visibility of device, 
led to restrictions in lifestyle, such as wearing black to disguise leakage. Some participants described a self-stigma, whereby the 
CD condition and its treatment had led to feelings of shame and a reduction in self-esteem.  
PIADS: In general, participant narratives, as well as the subsequent themes and sub-themes arising from analyses corresponded 
well to the 26 items in the PIADS, and the three main PIADS dimensions of Competence, Adaptability and Self-esteem appeared 
to adequately cover the issues experienced by participants. Most participants appeared to be able to complete the PIADS without 
difficulty, although the design of the form caused problems for some and even with the assistance of the PIADS glossary, some 
items were queried, or felt that more than one interpretation may apply depending on the circumstances. A few were confused by 
the reverse rating of the items confusion, embarrassment and frustration (i.e. positive ratings denote negative psychosocial 
impact).  
Several participants offered suggestions for new items for C-PIADS; one thought that ‘feeling down’ or ‘depression’ should be 
included, while another thought that ‘optimism’ was a better reflection of his state than well-being. Other participants suggested 
‘convenience’ – around storage, portability and disposal of devices, and ‘knowledge’ – understanding of CD and performance of 
the device. Potential new items, derived from interviews with the Canadian cohort were indicative of the stigma felt by participants; 
these included self-consciousness, fear of being ‘outed’, social acceptance, secrecy, isolation, revealing to others, social 
participation and intimate relations.  
Interpretation of results 
Expectations of device performance and device options were variable. There were no PIADS items that were judged to be 
inappropriate or irrelevant by more than a small proportion of the participants. The narratives indicated that the PIADS may be 
appropriate to assess quality of life effects attributable to CD intervention with some modification. Although several key self-stigma 
constructs are already present in the PIADS, these did not convey the degree of stigma associated with an activity (toileting) that 
is usually carried out (by adults) in private and the subsequent desire to conceal the condition and the device.  
 
Concluding message 
The PIADS appears to fundamentally address many, but not all, of the important psychosocial concerns of adults who have 
continence difficulties. A version for continence, the C-PIADS, will require modification of the PIADS and is likely to contain some 
new items. A better understanding of the stigma associated with CD and its ATDs will serve to inform modification. 
 
References 
1. Jutai J, Day H (2002). Psychosocial Impact of Assistive Devices Scale (PIADS) Technology and Disability 14:107–111 
2. Fischer D, Stewart AL, Bloch DA et al., (1999) Capturing the Patient's View of Change as a Clinical Outcome Measure. JAMA 
282(12):1157-1162 




Funding: The study was funded by the Bristol Urological Institute and the University of Ottawa Clinical Trial: No Subjects: 
HUMAN Ethics Committee: Research Ethics Boards of the Bruyère Research Institute and the University of Ottawa in Canada, 
and the Southmead Research Ethics Committee in the UK Helsinki: Yes Informed Consent: Yes  
 
